One in Two podcast - The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutation

 In this episode, we speak to Dr Colin Lindsay, Clinical Senior Lecturer at The Christie and The University of Manchester about the basic biology of lung cancer, focusing on:   The high incidence of lung cancer here in Manchester The differences between non-small cell and small-cell lung cancer Oncogenic drivers in lung cancer such as the KRAS mutation His work on the drug sotorasib which targets KRAS mutant cancer and has now been approved by the FDA and for use in the UK by NICE     Colin Lindsay's research profile  EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells  KRAS: Reasons for optimism in lung cancer On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma  Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Molecular characterization of primary and secondary resistance to RET inhibitors in patientswith advanced NSCLC and RET fusions (2022) https://www.ejcancer.com/article/S0959-8049(22)00871-1/fulltext